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ORIGINAL ARTICLE
Expression of NGAL-specific cells and mRNA levels correlate with inflammation
in the salivary gland, and its overexpression in the saliva, of patients with
primary Sj€ogren’s syndrome
Lara A. Aqrawia , Janicke Liaaen Jensena, Siren Fromreideb, Hilde Kanli Galtungc and Kathrine Skarsteinb,d
aDepartment of Oral Surgery and Oral Medicine, Institute of Clinical Odontology, University of Oslo, Oslo, Norway; bGade Laboratory for
Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; cDepartment of Oral Biology, University of Oslo, Oslo,
Norway; dDepartment of Pathology, Haukeland University Hospital, Bergen, Norway
ABSTRACT
Salivary gland involvement is a characteristic feature of primary Sj€ogren’s syndrome (pSS), where tissue
destruction is mediated by infiltrating immune cells, and may be accompanied by the presence of adi-
pose tissue. Optimally diagnosing this multifactorial disease requires the incorporation of additional
routines. Screening for disease-specific biomarkers in biological fluid could be a promising approach
to increase diagnostic accuracy. We have previously investigated disease biomarkers in saliva and tear
fluid of pSS patients, identifying Neutrophil gelatinase-associated lipocalin (NGAL) as the most upregu-
lated protein in pSS. In the current study, we aimed to explore for the first time NGAL expression at
the site of inflammation in the pSS disease target organ. Immunohistochemical staining was con-
ducted on minor salivary gland biopsies from 11 pSS patients and 11 non-SS sicca subjects, targeting
NGAL-specific cells. Additional NGAL/PNAd double staining was performed to study NGAL expression
in high endothelial venules, known as specialised vascular structures. Moreover, NGAL mRNA expres-
sion was measured utilising quantitative real-time polymerase chain reaction (qRT-PCR) on minor saliv-
ary gland biopsies from 15 pSS patients and 7 non-SS sicca individuals that served as tissue controls.
Our results demonstrated NGAL expression in acinar and ductal epithelium within the salivary gland
of pSS patients, where significantly greater levels of acinar NGAL were observed in pSS patients
(p< .0018) when compared to non-SS subjects. Also, acinar expression positively correlated with focus
score values (r2 ¼ 0.54, p< .02), while ductal epithelial expression showed a negative such correlation
(r2 ¼ 0.74, p< .003). Some PNADþ endothelial venules also expressed NGAL. An increase in NGAL
staining with increased fatty replacement was also observed in pSS patients. Concurringly, a 27%
increase in NGAL mRNA levels were also detected in the minor salivary glands of pSS patients when
compared to non-SS tissue control subjects. In conclusion, there is a positive association between
increase in NGAL expression and inflammation in the pSS disease target organ, which also coincides
with its previously demonstrated upregulation in the saliva of pSS patients. Additional functional anal-
yses are needed to better understand the immunological implications of this potential biomarker.
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In addition to the production of autoantibodies against
intracellular proteins Ro/SSA and La/SSB [1–4], the systemic
rheumatic autoimmune disorder of primary Sj€ogren’s syn-
drome (pSS) is also characterised by inflammation of the
exocrine glands [5,6]. The main target organs are the lacri-
mal and salivary glands, leading to the common sicca symp-
toms of dry eyes and dry mouth [7]. This inflammatory
process eventually results in the replacement of the glandu-
lar epithelium by infiltrating mononuclear cells that lead to
dysfunction and later destruction of the glands [6,8]. Hence,
routine assessment of minor salivary gland tissue has been
implemented as part of the diagnostic procedure when eval-
uating patients for pSS [9,10], and is particularly useful to
identify patients with glandular dysfunctions that do not
exhibit autoantibody production [11]. Interestingly, salivary
gland degeneration is usually coupled with adipose tissue
development in pSS [12]. A higher incidence of adipose tis-
sue replacement has been reported in pSS patients, [13]
where signalling pathways that promote adipose tissue
development, inflammation, and lymphoma have also been
identified [14]. Hence, infiltration of adipocytes within the
target organ of pSS patients seems to have a proinflamma-
tory function at the site of inflammation, in addition to the
infiltrating mononuclear cells.
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Considering the current diagnostic procedures available for
evaluating pSS, there is an unmet need for the incorporation of
non-invasive, more accurate diagnostics. Inspecting the prote-
ome of biological fluids and screening for disease-specific bio-
markers [15], utilising liquid chromatography-mass
spectrometry (LC-MS) [16,17], has therefore been in focus.
Consequently, the analysis of both saliva [15,18–24] and tear
fluid [25,26] has led to the identification of potential bio-
markers for pSS, such as Neutrophil gelatinase-associated lipo-
calin (NGAL, also known as LCN2), b-2 microglobulin
(B2MG), Lymphocyte-specific protein 1 (LSP1), interleukin-4
(IL-4), IL-5, and Clusterin (CLU) [16,23,27]. We have also
screened for disease biomarkers in pSS previously [26,28,29],
where NGAL was found to be the most upregulated protein in
stimulated whole saliva of pSS patients, and the only upregu-
lated biomarker detected in both saliva and tear fluid of these
patients. This iron-binding protein is involved in the innate
immune system, and is particularly responsible for the activa-
tion of neutrophils, and modulating autoantibody levels in sys-
temic lupus erythematosus [30,31]. NGAL has also been
reported to play an active part in systemic vasculitis [32] and
ulcerative colitis [33], in addition to suppressing bacterial infec-
tion [31,34]. Moreover, NGAL is routinely used as a diagnostic
marker in detecting kidney injury [35,36].
To date, NGAL expression has only been investigated in
normal human salivary gland tissue and salivary glands with
chronic sialadenitis [37]. Hence, given its upregulation in
saliva and tear fluid of pSS patients [26], and its inflamma-
tory involvement in other infectious and autoimmune dis-
eases, we wished to further explore the expression pattern of
NGAL at the site of inflammation in the pSS disease target
organ. By applying immunohistochemistry and quantitative
real-time polymerase chain reaction (qRT-PCR) on minor
salivary glands from pSS subjects and non-SS sicca controls,
in combination with findings from our previous LC-MS
analysis [26], we aimed to gain further insight into the
immunological involvement of NGAL.
Materials and methods
Study population
A total of 26 patients (22 females, 4 males) were included in the
study, recruited at the Department of Oral Surgery and Oral
Medicine, University of Oslo, Oslo, Norway. All participants
were classified with pSS according to the AECG criteria [38–40].
In addition, 18 female non-SS sicca subjects that were assessed
for pSS at the University of Oslo, but did not fulfil the AECG cri-
teria, and had little or no focal inflammation in their salivary
gland tissue, served as the non-SS tissue controls. Lower labial
minor salivary gland biopsies, taken by one oral and maxillofacial
surgeon (JLJ), were obtained from all participants (between the
years 2012 and 2019), formalin fixed, and paraffin embedded, fol-
lowed by staining with haematoxylin and eosin (H&E). The
stained tissue sections were then evaluated by one oral patholo-
gist (KS) in order to determine their focus score; defined as the
number of focal infiltrates with >50 mononuclear cells per
4mm2 glandular tissue. Further assessment for the presence of
germinal centre (GC)-like structures and fatty infiltration (FI)
was also conducted on the H&E stained tissue sections. Clinical
data and patients’ demographics are presented in Table 1 (pSS
patients) and Table 2 (non-SS sicca tissue controls). All partici-
pating individuals gave their written consent, and the Regional
Medical Ethical Committee of South-East Norway (#2010/1292-
1, REK2015/363) approved the study.
Immunohistochemistry
Single staining of NGAL
Formalin fixed, paraffin embedded minor salivary gland biop-
sies were sectioned using a microtome (4-6mm). The sections
were placed on SuperFrostVR Plus microscope slides (Fisher
Scientific, Waltham, MA, USA) and incubated overnight at
56 C. This was followed by deparaffinisation in xylene (Chemi
Teknik, Oslo, Norway), and rehydration through a graded etha-
nol series (100%, 96%, 70%) and TBS (Sigma-Aldrich). The
sections were then subjected to epitope retrieval with target
retrieval solution (pH 6.0) (Agilent Dako, Carpinteria, CA,
USA) using a microwave, at 950W for 7min, followed by
350W for 18min. Thereafter, the slides were allowed to cool
for 20min, and then washed in water until reaching room tem-
perature (approximately 5min).
Endogenous peroxidase activity was blocked using Dako
Real Peroxidase Blocking solution for 5min. The primary
antibody NGAL (Abcam, Cambridge, UK) was diluted
(1:25) in antibody diluent (Agilent Dako), then added to the
sections, and incubated for 60min in a humidified chamber.
The specificity of this primary antibody was verified by the
manufacturer through western blotting analysis and immu-
nohistochemistry. This was followed by incubation with
horseradish peroxidase (HRP)-conjugated BrightVision poly
HRP-Anti-Mouse secondary antibody (Immunologic,
Amsterdam, the Netherlands) for 30min. Thereafter, sec-
tions were incubated for 10min with diaminobenzidine
(DAB) (Agilent Dako). All incubations were performed at
room temperature, and TBS containing 0.1% Tween was
used as washing buffer (pH 7.6) between each step for
10min. Finally, the sections were counterstained with
Haematoxylin (Agilent Dako) for 5min, washed in water for
5min, then dehydrated through a graded ethanol series
(70%, 96%, 100%) and xylene. Finally, sections were
mounted under coverslips using pertex (Histolab).
Double-staining of NGAL and PNAd
A double-staining using NGAL (Abcam, Cambridge, UK) was
performed alongside PNAd (BD Pharmingen, San Diego,
California, USA) to target high endothelial venules. The same
procedure was conducted as described above, where inactiva-
tion of peroxidase and alkaline phosphatase was conducted
using Dako Dual Endogenous Enzyme Block (Agilent Dako).
NGAL was used as the first primary antibody (dilution of
1:50), and incubated at 4 C over night. As a secondary anti-
body, Goat Anti-Mouse AP (SouthernBiotech, Birmingham,
Alabama, USA) was applied for 30min (dilution 1:100 in Dako
antibody diluent). It was then developed using Vulcan fast red
chromogen (Biocare, Birmingham, UK) for 15min, and
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Table 1. Clinical characteristics of pSS patients included in the study.
Patient













1 52 F þ þ þ 8 þ 1 þ þ þ þ
2 54 F þ þ  1  2 þ þ  þ
3 60 F þ þ þ 3 þ 1 þ þ  
4 64 F þ þ  0  1 þ þ þ þ
5 55 F þ þ  <1  2 þ þ þ þ
6 35 F þ þ þ 3 þ 0 þ þ  
7 72 F þ þ  <1  0 þ   þ
8 71 F þ þ  0  2 þ þ þ þ
9 60 F þ þ  <1  2 þ þ þ þ
10 44 F þ þ þ 7 þ 1  þ þ þ
11 29 F þ þ þ 4 þ 1 þ þ þ þ
12 60 F þ þ  1  2 þ þ þ þ
13 64 M þ þ þ 2  0 þ þ þ þ
14 35 F þ þ þ 3 þ 0 þ þ  
15 43 F þ þ þ 10 þ 1 þ þ þ þ
16 47 M þ þ  3  0 þ þ þ þ
17 29 F þ þ þ 4 þ 1  þ þ þ
18 47 F þ þ þ 1  0 þ þ þ þ
19 49 F þ þ  1  0  þ  þ
20 49 F þ þ þ 1  1 þ þ þ þ
21 36 M þ þ þ 2  0 þ   
22 70 F þ   1  2 þ þ þ þ
23 23 F þ þ  1  0  þ þ 
24 56 F þ   1 þ 1 þ þ þ þ
25 82 M þ þ þ <1  2 þ þ þ 
26 46 F þ þ þ 2 þ 1 þ  þ þ
F: female; M: male; FI: fatty infiltration; GC: germinal centre.pSS patients included in the immunohistochemistry analysis, rest included in real-time PCR.Age was calculated based on the year of biopsy collection.Autoantibody production was assessed by ELISA.Values are the number of focal infiltrates/4mm2 tissue area containing >50 mononuclear cells.The degree of fatty infiltration was assessed, and the sections were scored blindly, where no or little fatty infiltration ¼ 0, moderate ¼ 1, and prominent
¼ 2.Values are in mm/5min; normal flow > 5mm/5min. ‘þ’ indicates dryness and tear secretion 5mm/5min.Values are in ml/15min; normal flow > 1.5ml/15min. ‘þ’ indicates dryness and unstimulated whole saliva secretion  1.5ml/15min.
Table 2. Clinical characteristics of non-SS sicca subjects included in the study.
Subject













1 48 F    <1 0 þ þ þ þ
2 65 F    0 2 þ þ þ þ
3 39 F    0 0 þ þ þ þ
4 44 F    0 0  þ þ þ
5 30 F    <1 0  þ þ þ
6 56 F    0 1 þ þ þ þ
7 41 F    0 0 þ þ þ þ
8 50 F    0 0 þ þ þ þ
9 47 F    <1 1 þ  þ þ
10 64 F    <1 0 þ þ þ þ
11 59 F    <1 0 þ þ þ þ
12 71 F    0 1 þ þ þ þ
13 56 F    0 1 þ þ þ þ
14 41 F    0 0 þ þ þ þ
15 39 F    0 0 þ þ  
16 64 F    0 1 þ þ þ þ
17 39 F    0 0 þ þ þ þ
18 51 F    0 0 þ þ þ þ
F: female; FI: fatty infiltration.pSS patients included in the immunohistochemistry analysis, rest included in real-time PCR.Age was calculated based on the year of biopsy collection.Autoantibody production was assessed by ELISA.Values are the number of focal infiltrates/4mm2 tissue area containing >50 mononuclear cells.The degree of fatty infiltration was assessed, and the sections were scored blindly, where no or little fatty infiltration ¼ 0, moderate ¼ 1, and prominent
¼ 2.Values are in mm/5min; normal flow > 5mm/5min. ‘þ’ indicates dryness and tear secretion 5mm/5min.Values are in ml/15min; normal flow > 1.5ml/15min. ‘þ’ indicates dryness and unstimulated whole saliva secretion  1.5ml/15min.
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washed in water for 5min. Denaturation was then conducted
with buffer pH 6, by means of a microwave at 950W for
3min, followed by 350W for 5min. Inactivation of peroxi-
dases was then achieved by incubating the sections with Dako
Real Peroxidase Blocking Solution (Agilent Dako) for 5min.
The sections were further incubated with PNAd (dilution
1:500) for 60min, followed by the secondary antibody
BrightVision poly HRP-Anti-Mouse (Immunologic,
Amsterdam, the Netherlands) for 30min. Vina Green
Chromogen (Biocare, Birmingham, UK) was then used to
develop the staining. Ultimately, all sections were washed in
water for 5min, counterstained with Haematoxylin (Agilent
Dako) for 10 s, dehydrated in an incubator at 56 C for
20min, followed by xylene for 2min, and finally mounted
with pertex (Histolab).
Evaluation of staining
The minor salivary gland sections were inspected using a light
microscope (Leica, DMLB, Leica Microsystems Wetzlar,
Wetzlar). This allowed the detection and quantification of
mononuclear cells, located in focal infiltrates and interstitially,
i.e. in close proximity to the acinar or ductal epithelium, as
part of routine procedure. Furthermore, the salivary gland sec-
tions were scored blindly by two investigators in parallel (KS,
LAA) for the presence of fatty deposition, in order to deduce
the fatty infiltration score (FI score). Numbers 0, 1, or 2 were
assigned during assessment of fatty replacement, where 0 was
considered negative, 1 was regarded moderate, while 2 repre-
sented prominent fatty infiltration.
Moreover, immunohistochemically stained sections were
concurrently analysed by two investigators (KS, LAA), and
the staining pattern was examined as an entity, and in rela-
tion to both focal inflammation and adipose tissue replace-
ment (FI-score) in the glands. Cells were regarded positively
stained when approximately 50% or more of the cell mem-
brane was stained. Here, a similar approach was applied to
score the stained salivary gland sections for NGALþ cells, as
for FI. In this regard, 0 represented detection of no NGALþ
cells, 1 reflected few to moderate numbers of positively
stained cells, and 2 represented prominent numbers of
NGALþ cells. This approach allowed the evaluation and
quantification of NGAL staining in the ductal epithelium,
and interstitially in the acinar epithelium within the salivary
gland of pSS and non-SS subjects.
Quantification of NGAL mRNA in salivary gland tissue
Salivary gland tissue preparation and RNA isolation
Minor labial salivary glands from 15 pSS patients and 7
non-SS tissue controls were used for RNA isolation and
qRT-PCR. The fresh glands were placed in RNAlater
(Sigma-Aldrich, St Louis, MO) and kept at 4 C before being
frozen at 150 C. RNeasy Mini kit (Qiagen, Valencia, CA)
was used for total RNA extraction, according to the manu-
facturer’s instructions, and RNA purity and quantification
were measured with a NanoDrop spectrophotometer
(NanoDrop Technologies Inc., Wilmington, DE).
qRT-PCR
Quantification of mRNA was performed as previously
described [41]. In brief, a total of 200 ng RNA was used per
10 ml reverse transcriptase step. Complementary DNA
(cDNA) was generated using the Reverse Transcription
Core Kit (Eurogentec, Seraing, Belgium), with a mix of
reverse transcriptase enzyme, RNAse inhibitor, MgCl, dNTP
and 10 buffer. Each cDNA synthesis was performed in a
total volume of 30 ml for 10min at 25 C, then at 48 C for
30min and terminated by incubation for 5min at 95 C.
Detection of NGAL and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was carried out using Assay-on-
Demand TaqMan Gene Expression Assay (AOD, Applied
Biosystems, Foster City, CA). Each qRT- PCR reaction con-
sisted of 1 AOD mix, 1 qPCR Takyon Low Rox Probe
MasterMix dTTP Blue (Eurogentec, Seraing, Belgium) and
10 ml cDNA (diluted 1:2.5 ml with H2O) as the template.
qRT- PCR reactions were performed in a 96-wells PCR
reaction plate on AriaMx Real-Time PCR System (Agilent
Technologies, Santa Clara, CA) for 40 cycles (95 C for 15 s
and 60 C for 1min) after an initial 10min incubation at
95 C. The data were normalised to GAPDH as endogenous
control, and a Non-Template Control (NTC) was included
for each run to validate the assay. For each experiment
every individual sample was run in duplicates. The relative
amount of NGAL mRNA was standardised to that of
GAPDH mRNA using DCq ¼ [Cq (target gene)  Cq (ref-
erence gene)] and displayed as 2(DCq).
Proteomic analysis of saliva
Stimulated whole saliva was formerly collected from another
cohort of 27 pSS patients and 32 healthy controls by chewing
on a paraffin block (Paraffin Pellets, Ivoclar Vivadent, Shawn,
Lichtenstein, Germany) for 5min. This was followed by prote-
omic analysis, conducted in a previous study (Supplementary
file 1) [26]. In brief, in-solution protein digestion was con-
ducted, followed by LC-MS using an Ultimate 3000
RSLCnano-UHPLC system connected to a Q Exactive mass
spectrometer (Thermo Fisher Scientific, Bremen, Germany).
Scaffold (version Scaffold_4.4, Proteome Software Inc.,
Portland, OR, USA) was then applied to allow the validation of
the MS/MS-based peptide and protein identifications. Spectral
counts were thus provided for each protein (Supplementary file
1), and the most upregulated protein found in stimulated whole
saliva of these patients, namely NGAL, was identified based on
our former proteomics data analysis [26].
Statistical analysis
The Mann-Whitney U-test was used for comparing two
groups (non-normal distribution of values). The Spearman
non-parametric correlation test was used to examine correl-
ation between parameters. All calculations were performed
using Prism 8 (GraphPad). A p-value <.05 was considered
statistically significant.
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Results
Expression of NGAL in the salivary gland tissue of pSS
patients correlates with inflammation
Cells expressing NGAL were detected in the acinar epithe-
lium of pSS patients (Figure 1(A,B)), while little to no stain-
ing was observed in the non-SS subjects (Figure 1(C,D)).
A quantification of NGAL staining revealed significantly
greater NGAL expression in the acini of pSS patients as
compared to non-SS sicca subjects (p< .0018) (Figure 1(E)).
Furthermore, an increase in degree of acinar staining with
increasing focus score was also observed in patients with
pSS (Figure 1(F)), where a positive correlation between
acinar NGAL staining and focus score was also identified
Figure 1. NGAL expression in the acinar epithelium of salivary glands from patients with pSS. (A) NGAL (brown) is detected in acinar epithelium within the salivary
glands of pSS patients. (B) A magnified representation of (A), where the arrowheads indicate NGAL staining of the acinar epithelium. (C) Little to no NGAL staining
was observed in the non-SS subjects. (D) A magnified representation of (C). E) A quantification of NGAL staining within the salivary gland tissue reveals significantly
greater NGAL expression in the acini of pSS patients as compared to non-SS sicca subjects (p< .0018). (F) Increase in degree of acinar NGAL staining with increas-
ing focus score in patients with pSS. (G) Positive correlation between acinar NGAL staining and focus score in pSS patients (p< .02, r2 ¼ 0.54).
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(r2 ¼ 0.54, p< .02) (Figure 1(G)). No striking difference
was observed in the non-SS sicca group with regard to aci-
nar staining and focus score (data not shown).
Interestingly, NGALþ cells were also detected in the duc-
tal epithelium within the pSS target organ (Figure 2(A,B)),
with similar levels of NGAL expression in the ductal epithe-
lium of pSS patients as compared to non-SS sicca subjects
(Figure 2(C)). However, contrary to the expression pattern
in acinar epithelium, a decrease in degree of ductal staining
was detected in pSS patients with increasing focus score
(Figure 2(D)), resulting in a negative correlation between
ductal NGAL staining and focus score in these patients (r2
¼ 0.74, p< .003) (Figure 2(E)). Meanwhile, no noteworthy
difference was observed in the non-SS sicca group with
regard to ductal NGAL staining and focus score (data
not shown).
Moreover, NGAL staining was also expressed in some
blood vessels in the salivary gland tissue. To confirm
Figure 2. NGAL expression in the ductal epithelium of salivary glands from patients with pSS. (A) NGAL (brown) is detected in ductal epithelium within the salivary
glands of pSS patients. (B) A magnified representation of (A), where the arrowheads indicate NGAL staining of the ductal epithelium. (C) A quantification of NGAL
staining within the salivary gland tissue shows similar levels of NGAL expression in the ductal epithelium of pSS patients as compared to non-SS sicca subjects. (D)
Decrease in degree of ductal NGAL staining with increasing focus score in patients with pSS. E) Negative correlation between ductal NGAL staining and focus score
in pSS patients (p< .003, r2 ¼ 0.74).
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whether NGAL was indeed binding to specialised vascular
structures known as high endothelial venules, double immu-
nohistochemical staining was performed utilising NGAL in
combination with PNAd for the detection of high endothe-
lial venules. Some double-positive blood vessels expressing
both NGAL and PNAd were thus detected within the target
organ of pSS patients (Figure 3).
NGAL detection in areas of close proximity to adipose
tissue within the target organ of pSS patients
Through immunohistochemical detection of NGALþ cells in
the pSS target organ, we were able to study the expression
pattern of NGAL in relation to fatty replacement. Indeed,
NGALþ cells were detected in close proximity to adipose
tissue within the salivary glands of pSS patients (Figure
4(A,B)). An increase in both acinar and ductal NGAL stain-
ing was observed with increasing FI score in pSS patients
(Figure 4(C,D)). No notable differences were observed in
the non-SS sicca group with regard to FI score and NGAL
expression (data not shown).
Enhanced NGAL mRNA expression in the salivary glands
of pSS patients
In order to verify the detection and increase of NGALþ cells
in the salivary gland tissue of pSS patients, as compared to
non-SS sicca controls, qRT-PCR was conducted. The
median of 2(DCt) was calculated and presented in 104,
where DCt ¼ Ct (NGAL) – Ct (GAPDH). Our result indi-
cated a 27.5% increase in NGAL (pSS 1.02, non-SS 0.82;
p< .8) mRNA levels in the salivary glands of pSS patients
when compared to non-SS tissue controls (Figure 5).
Overexpression of NGAL in the saliva of pSS patients
analysed by LC-MS
We have previously conducted a proteomic analysis on
stimulated whole saliva collected from a different cohort of
pSS patients and healthy controls (Supplementary file 1)
[26]. Our former analysis revealed that the most upregulated
protein identified in stimulated whole saliva of pSS patients
was indeed NGAL. In the current study, we graphically
illustrate for the first time the spectral counts measured in
the saliva of each of those participants from our previous
study, hence providing a visual representation of NGAL
abundance, where significantly greater amounts of NGAL
protein were observed in the pSS patients as compared to
healthy controls (Figure 6).
Discussion
Delineating the development of a complex and heteroge-
neous disease such as pSS has indeed proven challenging
over the years. As salivary gland involvement plays an
essential role in disease progression and pathogenesis,
increasing diagnostic accuracy in pSS by searching for
potential biomarkers through LC-MS approaches should
also be accompanied by investigating and understanding
the expression of such biomarkers at the site of inflamma-
tion in the pSS disease target organ. We have previously
identified potential novel disease biomarkers in saliva and
tear fluid of pSS patients [26,28], where NGAL was the
most upregulated protein in stimulated whole saliva of pSS
patients, and the only biomarker that was upregulated in
both saliva and tear fluid of pSS patients when compared
to healthy controls, making it an ideal candidate for fur-
ther investigation. Thus far, the expression of NGAL has
only been explored in normal human salivary gland tissue
and salivary glands with chronic sialadenitis [37]. In the
current study, we aimed to explore the expression pattern
of NGAL in minor salivary gland biopsies from pSS
Figure 3. NGAL expression in the blood vessels of salivary glands from patients with pSS. Double immunohistochemical staining utilising NGAL (pink) and PNAd
(green); for the detection of high endothelial venules, confirms NGAL expression in some of the blood vessels within the pSS target organ. The arrowheads indicate
a double-positive blood vessel expressing both NGAL and PNAd.
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subjects and non-SS sicca controls. Together, our findings
could aid in providing further insight into pSS pathogen-
esis, diagnostic accuracy, and may also contribute to tailor-
ing current therapeutic strategies [42,43].
We have shown cells expressing NGAL in the acinar epi-
thelium and ductal epithelium within the salivary glands of
pSS patients. However, an interpretation of NGAL staining
revealed significantly greater NGALþ cells in the acini of
pSS patients as compared to non-SS sicca subjects, while
similar levels of NGAL expression was observed in the duc-
tal epithelium of pSS patients and non-SS sicca tissue con-
trols. Moreover, an increase in degree of acinar NGAL
staining was found in pSS patients with increasing focus
score, with a contrasting decrease in degree of ductal NGAL
staining as focus score values increase. This positive correl-
ation of NGAL expression with inflammation in the acinar
epithelium of pSS salivary gland tissue, and negative associ-
ation with expression in the ductal epithelium, could be the
result of the cellular functions of this protein. Since NGAL
is also involved in regulating neutrophils and supressing
infection [36], and could play a part in the initial phases of
disease and innate immunity [30], one would therefore sus-
pect it to be expressed at early stages of disease develop-
ment, as pathogenic inflammation targets the salivary
glands, and also interstitially [44]. However, further func-
tional studies are needed to verify the functional role of
NGAL in relation to neutrophil expression in pSS.
Interestingly, NGAL was expressed on some endothelial
cells in the glandular tissue, as confirmed by our double
immunohistochemical staining of PNAd and NGAL. The
Figure 4. NGAL expression in relation to fatty infiltration. (A) NGAL (brown) is expressed in close proximity to adipose tissue in the salivary glands of pSS patients,
where the arrowheads indicate areas of fatty infiltration. (B) A magnified representation of (A), where the arrowheads pinpoint NGAL stained areas in close proxim-
ity to the adipocytes. (C) Increase in NGAL acinar staining with increasing FI score in pSS subjects. (D) Increase in NGAL ductal staining with increasing FI score in
patients with pSS.
Figure 5. Expression of NGAL mRNA in salivary gland tissue using qRT-PCR.
Enhanced NGAL mRNA expression is observed in the salivary glands of pSS
patients, as compared to non-SS sicca subjects, with a 27.5% increase in the
patient group (pSS 1.02, non-SS 0.82; p< .8). The mean of 2(DCt) was calcu-
lated and presented in 104, where DCt ¼ Ct (NGAL) – Ct (GAPDH).
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formation of these high endothelial venules has previously
been shown at the site of inflammation in pSS, where they
facilitated migration of immune cells into the lymphoid
organs by binding certain chemokines [45]. Hence, NGAL
expression in some of these high endothelial venules identi-
fied in our current analysis may indicate a regulatory role of
navigating the immune cells into the glandular tissue [45].
Additionally, the detection of NGALþ cells in close proxim-
ity to adipose tissue within the salivary glands of pSS
patients is a further indication of NGAL involvement in the
inflammatory process, as shown by the increase in NGALþ
cells with increasing FI score in these patients.
The overexpression of NGALþ cells in the salivary glands
of pSS patients coincides with increased NGAL mRNA
expression. Moreover, enhanced NGAL detection in the pSS
disease target organ corresponds with its upregulation in the
saliva and tear fluid of pSS patients, as shown by our previ-
ous LC-MS analyses [26,28,29]. In the current study, we
illustrated for the first time a representation of NGAL abun-
dance where the spectral counts measured in the saliva of
each participant revealed significantly greater amounts of
NGAL protein in the pSS patients as compared to healthy
controls. This strengthens the notion of involvement and
over-activation of the innate immune system in pSS through
the upregulation of NGAL and other pro-inflammatory
related proteins in the pSS patients to form protein-protein
network interactions.
Conclusions
By applying immunohistochemistry and qRT-PCR on minor
salivary glands from pSS patients and non-SS sicca subjects,
in combination with previous outcomes from our LC-MS
analysis on saliva [26], we have now gained further insight
into the expression pattern of NGAL. Our results indicated
a positive association between increase in NGALþ cells in
the pSS disease target organ and inflammation, particularly
in the acinar epithelium, as supported by increased NGAL
mRNA levels in the patients. This also coincides with the
previously detected upregulation of NGAL in the saliva of
pSS patients. Accordingly, additional functional analyses are
needed to better understand the immunological implications
of this potential biomarker.
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